Janux Therapeutics Stock Performance
| JANX Stock | USD 32.60 0.09 0.28% |
The company retains a Market Volatility (i.e., Beta) of 2.19, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Janux Therapeutics will likely underperform. At this point, Janux Therapeutics has a negative expected return of -0.29%. Please make sure to check out Janux Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Janux Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Janux Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (0.28) | Five Day Return (13.83) | Year To Date Return (38.77) | Ten Year Return 29.62 | All Time Return 29.62 |
1 | Disposition of 15000 shares by David Campbell of Janux Therapeutics at 67.0 subject to Rule 16b-3 | 12/03/2024 |
2 | Janux Therapeutics Announces Pricing of 350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants | 12/05/2024 |
3 | Acquisition by Meyer Andrew Hollman of 9880 shares of Janux Therapeutics at 20.24 subject to Rule 16b-3 | 12/19/2024 |
4 | Disposition of 25000 shares by David Campbell of Janux Therapeutics at 56.1922 subject to Rule 16b-3 | 12/24/2024 |
5 | Janux therapeutics CEO David Campbell sells 1.4 million in stock - Investing.com | 12/27/2024 |
6 | RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc | 12/31/2024 |
7 | Acquisition by Meyer Andrew Hollman of 63000 shares of Janux Therapeutics at 53.24 subject to Rule 16b-3 | 01/02/2025 |
8 | Disposition of 5000 shares by David Campbell of Janux Therapeutics at 60.0008 subject to Rule 16b-3 | 01/07/2025 |
9 | Disposition of 5768 shares by Meyer Andrew Hollman of Janux Therapeutics at 54.5111 subject to Rule 16b-3 | 01/14/2025 |
10 | Janux Therapeutics, Inc. Promotes Zachariah McIver to Chief Medical Officer -January 24, 2025 at 0401 pm EST - Marketscreener.com | 01/24/2025 |
11 | Disposition of 100 shares by Meyer Andrew Hollman of Janux Therapeutics at 43.6 subject to Rule 16b-3 | 02/03/2025 |
12 | Janux Therapeutics Trading Down 4.2 percent Heres Why | 02/04/2025 |
13 | Janux therapeutics chief business officer sells shares worth 140,999 - MSN | 02/07/2025 |
14 | Insider Trading | 02/13/2025 |
15 | Acquisition by Avalon Ventures Xi, L.p. of 2070 shares of Janux Therapeutics at 13.22 subject to Rule 16b-3 | 02/26/2025 |
| Begin Period Cash Flow | 52.2 M |
Janux |
Janux Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,521 in Janux Therapeutics on November 29, 2024 and sell it today you would lose (1,261) from holding Janux Therapeutics or give up 27.89% of portfolio value over 90 days. Janux Therapeutics is currently does not generate positive expected returns and assumes 7.8943% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than Janux, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Janux Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Janux Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Janux Therapeutics, and traders can use it to determine the average amount a Janux Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0373
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | JANX |
Estimated Market Risk
| 7.89 actual daily | 70 70% of assets are less volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Janux Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Janux Therapeutics by adding Janux Therapeutics to a well-diversified portfolio.
Janux Therapeutics Fundamentals Growth
Janux Stock prices reflect investors' perceptions of the future prospects and financial health of Janux Therapeutics, and Janux Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Janux Stock performance.
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0993 | ||||
| Operating Margin | (81.64) % | ||||
| Current Valuation | 1.28 B | ||||
| Shares Outstanding | 58.63 M | ||||
| Price To Book | 2.91 X | ||||
| Price To Sales | 146.84 X | ||||
| Revenue | 8.08 M | ||||
| Gross Profit | (46.77 M) | ||||
| EBITDA | (71.02 M) | ||||
| Net Income | (58.29 M) | ||||
| Cash And Equivalents | 338.76 M | ||||
| Cash Per Share | 8.15 X | ||||
| Total Debt | 24.54 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 21.08 X | ||||
| Book Value Per Share | 12.54 X | ||||
| Cash Flow From Operations | (50.58 M) | ||||
| Earnings Per Share | (1.17) X | ||||
| Market Capitalization | 1.92 B | ||||
| Total Asset | 380.41 M | ||||
| Retained Earnings | (168.76 M) | ||||
| Working Capital | 336.21 M | ||||
About Janux Therapeutics Performance
Evaluating Janux Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Janux Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Janux Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (273.42) | (287.10) | |
| Return On Tangible Assets | (0.15) | (0.14) | |
| Return On Capital Employed | (0.23) | (0.22) | |
| Return On Assets | (0.15) | (0.14) | |
| Return On Equity | (0.19) | (0.18) |
Things to note about Janux Therapeutics performance evaluation
Checking the ongoing alerts about Janux Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Janux Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Janux Therapeutics generated a negative expected return over the last 90 days | |
| Janux Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 8.08 M. Net Loss for the year was (58.29 M) with loss before overhead, payroll, taxes, and interest of (46.77 M). | |
| Janux Therapeutics currently holds about 338.76 M in cash with (50.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.15. | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates |
- Analyzing Janux Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Janux Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Janux Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Janux Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Janux Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Janux Therapeutics' stock. These opinions can provide insight into Janux Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.